SGVP OI 44-5, 16 April 2013

“TALLman lettering will be used by the UD prepackaging machine and on the pharmacy self tags to
differentiate between look-alike, sound-alike medications. Medications requiring TALLman lettering will be
identified by the FDA Name Differentiation list provided in current Lexi-Comp’s Drug Information Handbook.”
                                                  59th Medical Wing
               2013/2014 Look-Alike, Sound-Alike Medications
                               “CONFUSING DRUG NAMES IS A COMMON SYSTEM FAILURE”
ALPRAZolam (Xanax®) & LORazepam (Ativan®)
Actos® (pioglitazone) & Actonel® (risedronate)
Aricept® (donepezil) & Aciphex® (RABEprazole) & Azilect® (rasagiline)
Atarax® (hydrOXYzine) & Adderall® (amphetamine salts) & Inderal (propranolol)
CeleXA® (citalopram) & CeleBREX® (celecoxib) & ZyPREXA® (OLANZaprine)
cloNIDine (Catapres®) & KlonoPIN® (clonazePAM)
clonazePAM (KlonoPIN®) & LORazepam (Ativan®)
DULoxetine (Cymbalta®) & FLUoxetine (PROzac®)
Flonase® (fluticasone) nasal & Flovent® (fluticasone) oral inhalation
GlipiZIDE (Glucotrol®) & glyBURIDE (Micronase®)
guaiFENesin (Mucinex®) & guanFACINE (Tenex®)
HYDROmorphone (Dilaudid®) & Morphine (Avinza®, Kadian®, MS Contin® , Oramorph® SR)
hydrOXYzine (Atarax®, Vistaril®) & HydrALAZINE (Apresoline®)
Keflex® (cephalexin) & Keppra® (levETIRAcetam)
Insulin products: (NPH, Regular, Novolog®: aspart, Humalog®:lispro, Levemir®: detemir, Lantus®: glargine)
LamISIL® (terbinafine) & LaMICtal® (lamoTRIgine) & lamiVUdine (Epivir®)
metFORMIN (Glucophage®) & metroNIDAZOLE (Flagyl®)
Plavix® (clopidogrel) & Paxil® (PARoxetine)
PrilOSEC® (omeprazole) & PROzac® (FLUoxetine)
traZODone (Desyrel®) & traMADol (Ultram®)
tretinoin (Retin-A®) & ISOtretinoin (Accutane®)
Toprol® XL (metoprolol succinate) & Topamax® (topiramate)
Yaz® (ethinyl estradiol/drospirenone 0.02-3mg) & Yasmin® (ethinyl estradiol/drospirenone 0.03-3mg)
ZyrTEC® (cetirizine) & ZyPREXA® (OLANZapine)
Zantac® (ranitidine) & Xanax® (ALPRAZolam)
                                                                                      59MDWVA 44-110, 12 December 2013
                                                          Releasability: There are no releasability restrictions on this publication.
                                                                                      Per MDWI 44-115, OPR 59 MDW/SGVPO
                                                                                   Supersedes 59MDWVA 44-110, 10 May 2012
